RxDoctor Payments Data

Steven Yang

Psychiatric/Mental Health · West Covina, CANPI 1487204921

Payments from drug & device makers

$2,853in general payments, 2019–2025

Across 116 payments — averaging $24.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$927
  • Johnson & Johnson$702
  • Teva Pharmaceuticals USA, Inc.$399
  • E.r. Squibb & Sons, L.L.C.$326
  • Otsuka America Pharmaceutical, Inc.$174
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$164
  • plus $160 from 4 others

What the payments were for

  • Food & beverage$2,853100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,853 in reported general payments places this provider in the 85th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$6,423
Medicare patients
28
Services billed
81

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate51$152,574
LybalviOlanzapine/Samidorphan Malate41$61,421
OzempicSemaglutide13$12,502
JanuviaSitagliptin Phosphate12$6,902
Clozapine30$4,736
Aripiprazole34$2,522
Divalproex Sodium ErDivalproex Sodium15$1,994
Atorvastatin Calcium126$1,848
Bupropion XlBupropion Hcl29$1,359
Divalproex Sodium29$1,291
Quetiapine Fumarate57$1,244
Olanzapine63$1,234
Metformin Hcl67$722
Risperidone33$671
Glipizide16$622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$702$152,57451 claims
Alkermes, Inc.Lybalvi$927$61,42141 claims
Almatica Pharma LLCSertraline Hcl$24$7627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in West Covina

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →